FDA warns of potential contamination of drug shipments from explosions in Tianjin City
![](/46/pdcnewsitem/03/84/91/FDA.jpg)
The increased surveillance resulted in the detection of hydrogen cyanide contamination in two shipments of drugs from Tianjin Tianyao Pharmaceuticals Co., Ltd.
FDA has alerted drug compounders and manufacturers that drug shipments from Tianjin, China may be at risk of chemical contamination. FDA increased surveillance of drug shipments following two massive explosions at Tianjin Dongjiang Port Ruihai International Logistics Co., a chemical warehouse, in August 2015.
The increased surveillance resulted in the detection of hydrogen cyanide contamination in two shipments of drugs from Tianjin Tianyao Pharmaceuticals Co., Ltd. (Tianjin Tianyao) located in Tianjian, approximately 30 kilometers (18 miles) from the explosion site. Tianjin Tianyao also sent two other drug shipments to the US, since the explosion, that were tested and released after hydrogen cyanide was not detected in the shipments. The shipments appear to have been intended for use in pharmacy compounding.
The contaminated shipments have been stopped and will not be allowed into the US. The FDA is working with the Chinese Food and Drug Administration (CFDA) on this issue.
FDA’s increased monitoring is intended to prevent the import into the US of drugs that may be contaminated by toxic chemicals associated with the explosions. While information related to the explosion is limited, more than 40 different types of chemicals were discovered at the blast site.
It is the responsibility of companies that obtain drugs - including finished drug products, active pharmaceutical ingredients (APIs) and excipients - from the Tianjin City region to take appropriate precautions to ensure the quality of these products before they are distributed and/or used to further manufacture or compound drugs or drug products.
Manufacturers and compounders obtaining drug ingredients must know the source of the ingredients. Companies in the US with questions about the drug ingredients they order or receive, particularly from the Tianjin City area, should contact the foreign manufacturer for information. Companies must remain vigilant to ensure that all shipments are free from contamination associated with the explosion and not contaminated in any way.
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance